- Australia
- /
- Medical Equipment
- /
- ASX:CBL
Control Bionics Full Year 2024 Earnings: AU$0.037 loss per share (vs AU$0.062 loss in FY 2023)
Control Bionics (ASX:CBL) Full Year 2024 Results
Key Financial Results
- Revenue: AU$6.36m (up 13% from FY 2023).
- Net loss: AU$5.91m (loss widened by 5.0% from FY 2023).
- AU$0.037 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Control Bionics shares are up 2.3% from a week ago.
Risk Analysis
Before you take the next step you should know about the 5 warning signs for Control Bionics (2 are significant!) that we have uncovered.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ASX:CBL
Control Bionics
Engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally.
Excellent balance sheet moderate.